279727
CAS Number
36167-63-2|Free Base: 69756-53-2Grade
Highly PurifiedMDL Number
MFCD00879136Molecular Formula
C26H30Cl2F3NO•HClMolecular Weight
536.88EU Commodity Code
38220090Shipping Temp
RTStorage Temp
4°CHalofantrine HCl
1,3-Dichloro-a-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrenemethanol hydrochloride, Halfan
Halofantrine is a drug that belongs to the class of antimalarial drugs. Halofantrine is used for the treatment of malaria and other infectious diseases, such as listeriosis, bacterial septicaemia, and toxoplasmosis. Halofantrine can be administered orally or intravenously. It is metabolized in vivo to form halofantrine HCl (HFA), which has a greater effect on serum prolactin levels and cardiac effects than the parent compound. In vitro assays have shown that HFA causes toxicity to epidermal cells and inhibits polymerase chain reaction (PCR) activity in mammalian cells. The toxic effects on skin cells are probably due to inhibition of DNA synthesis and protein synthesis. There are also reports of cardiotoxicity in patients given high doses of HFA for prolonged periods (>3 months). In addition, HFA is associated with metabolic disorders including hypokalemia, hyperglycemia, and hypophosphatemia.
Synonyms
1,3-Dichloro-a-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrenemethanol hydrochloride, Halfan
CAS No
36167-63-2 Free Base: 69756-53-2
Molecular Formula
C26H30Cl2F3NO•HCl
Appearance
White to off-white powder
Melting Point
198-200°C (lit)
Storage and Stability
Store at 4ºC. Stable for 6 months after receipt.
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Toxicity and Hazards
All products should be handled by qualified personnel only, trained in laboratory procedures.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
1. Schmidt, L.H., et al.: Antimicrob. Agents Chemother., 14, 292 (1978). 2. Hines, J.W., et al.: J. Pharm. Sci., 74, 433 (1985). 3. Bryson, H.M., et al.: Drugs, 43, 236 (1992)USBio References
No references available